L. Sas

A phase II study of the combination of endocrine treatment and bortezomib in patients with endocrine-resistant metastatic breast cancer.

P. V. van Dam, W. Tjalma, P. Vermeulen, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract 3919: Novel model to study NFkB driven resistance to endocrine treatment in breast cancer

D. Peeters, P. Vermeulen, L. Dirix, 2012 .

A phase II study of the combination of endocrine treatment and bortezomib in patients with endocrine-resistant metastatic breast cancer.

P. V. van Dam, W. Tjalma, P. Vermeulen, 2011, Oncology reports.

The interaction between ER and NFκB in resistance to endocrine therapy

P. V. van Dam, P. Pauwels, P. Vermeulen, 2012, Breast Cancer Research.

The interaction between ER and NFκB in resistance to endocrine therapy

P. Pauwels, P. van Dam, P. Vermeulen, 2012, Breast Cancer Research.

Contribution of ER and NF-κB to endocrine resistance in inflammatory breast cancer

P. Vermeulen, L. Dirix, F. Lardon, 2014 .

Decreased expression of ABAT and STC2 hallmarks ER‐positive inflammatory breast cancer and endocrine therapy resistance in advanced disease

F. Bertucci, J. Foekens, A. Sieuwerts, 2015, Molecular oncology.